Caribou Biosciences (CRBU) Payables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Payables data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Payables fell 9.55% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 9.55% YoY) and the FY2025 annual result came in at $5.8 million, up 133.56% from the prior year.
• Payables fell to $3.5 million in Q1 2026 per CRBU's latest filing, from $5.8 million in the prior quarter.
• Across five years, Payables topped out at $5.9 million in Q1 2024 and bottomed at $426000.0 in Q2 2022.
• The 5-year median for Payables is $3.1 million (2023), against an average of $3.0 million.
• The widest annual swing landed in 2022, when Payables plunged 89.43%; it then jumped 940.61% in 2023.
• Tracing CRBU's Payables over 5 years: stood at $1.1 million in 2022, then surged by 172.25% to $3.1 million in 2023, then decreased by 20.64% to $2.5 million in 2024, then jumped by 133.56% to $5.8 million in 2025, then tumbled by 39.43% to $3.5 million in 2026.
• Per Business Quant, the three latest CRBU Payables figures stand at $3.5 million (Q1 2026), $5.8 million (Q4 2025), and $3.8 million (Q3 2025).

Peer Comparison